Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent
In Brief: GAO Says Congress Should Re-Examine Delaney Clause, Consider Making It More Flexible
CALGB Grant OKed, But Group May Lose Support For Its Non-Hematologic Segments
Aging Institute Encourages Cancer Investigators To Include Elderly
BRMP Investigators Find New Lung Tumor Antigen, Seek Developers
Summit Conference Reviews Leads In Leukemia, Lymphoma
Cell Behavior Changes Noted At Baltimore Symposium
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









